FDA team describes lectin microarray for rapid glycan‑epitope profiling of intact antibodies Dr. Bao Lin Zhang outlined a first‑ and second‑generation lectin microarray that the FDA team developed to profile glycan epitopes on intact antibodies, reporting high specificity in engineered anti‑HER2 tests and comparable epitope profiles across adalimumab biosimilars.

Dr. Bao Lin Zhang unveiled a groundbreaking lectin microarray that promises rapid and precise glycan-epitope profiling of therapeutic antibodies, a game-changer for biosimilar comparability!

Click to read more!

#US #CitizenPortal #BiotechInnovation #TherapeuticAntibodies #FDALectins